Head and Neck Adenoid Cystic Carcinoma — Variants & evidence

Head and Neck Adenoid Cystic Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

2 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items (2 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR2 S252W1
Erdafitinib	Salivary Gland Adenoid Cystic Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID13161 In the phase II NCI-MATCH EAY131-K2 trial, a patient with high-grade adenoid cystic carcinoma of the submandibular gland harboring an FGFR2 S252W (p.Ser252Trp) mutation achieved a partial response to … (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC	civic
IGF1R Overexpression1
Crizotinib + Gefitinib + LinsitinibCombination	Salivary Gland Adenoid Cystic Carcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID9024 Within a preclinical study 15 patient samples with adenoid cystic carcinoma MYB-NFIB fusion activation loop can be modulated through AKT-dependent signaling induced by IGF1R overexpression and downreg… (full text at CIViC) PMID 28954282 · Andersson et al., 2017 · Open in CIViC	civic

Data updated 20 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.